Is telehealth allowed to prescribe Mounjaro in New York?

If you’ve been considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you may be wondering: Can I get these prescriptions through telehealth, or do I need to visit a doctor in person? The short answer is yes—in most cases, you can legally obtain these medications through telehealth in the United States. But the specifics depend on where you live and what your state requires.

This guide breaks down everything you need to know about accessing weight loss medications via telemedicine, including federal and state regulations, what to expect during your virtual consultation, and how to find safe, reputable telehealth providers.

Understanding Federal Telehealth Rules for Weight Loss Medications

Are GLP-1 Medications Controlled Substances?

One of the most important things to understand is that GLP-1 medications like Wegovy (semaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are not controlled substances. This distinction matters because federal law—specifically the Ryan Haight Act—requires an in-person exam before prescribing controlled substances (like Adderall or certain pain medications) via telehealth.

Since GLP-1 weight loss medications are unscheduled, federal law does not require an in-person visit before a provider can prescribe them through telemedicine. This means that under federal regulations, a licensed healthcare provider can evaluate you via video consultation and electronically send your prescription to a pharmacy.

COVID-Era Telehealth Flexibilities: What’s Still in Effect?

During the COVID-19 pandemic, the Drug Enforcement Administration (DEA) temporarily waived the in-person requirement for controlled substances to expand access to telehealth care. While these flexibilities primarily affect medications like ADHD treatments and opioid addiction therapies, they’ve also helped normalize telehealth prescribing across all areas of medicine—including weight management.

As of December 2025, the DEA has extended these telehealth flexibilities for controlled substances through December 31, 2025. While this doesn’t directly impact GLP-1 medications (which were never restricted), it signals ongoing federal support for telemedicine as a legitimate care delivery method.

The bottom line: For non-controlled medications like Wegovy and Ozempic, telehealth prescribing has been—and remains—fully legal under federal law.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Telehealth Rules: What You Need to Know

While federal law provides a baseline, individual states can impose additional requirements for telehealth prescribing. Some states require an initial in-person exam, periodic follow-ups, or specific documentation for weight loss treatment. Others have streamlined their rules to make telehealth as accessible as possible.

States Requiring an Initial In-Person Exam

A handful of states mandate that patients undergo an in-person physical examination before or shortly after starting telehealth treatment for weight loss medications:

• Arkansas: Among the most restrictive states for telemedicine. An initial in-person exam is required to establish a valid provider-patient relationship.
• Delaware: Requires an initial physical exam in person before prescribing weight loss medications via telehealth.
• Georgia: State policy requires an in-person exam prior to telehealth prescribing of obesity medications.
• Mississippi: Expects an initial in-person evaluation for weight management therapy.
• New Jersey: Has strict Board of Medicine rules requiring a comprehensive initial evaluation, including physical exam, lab work, and psychological screening.
• North Dakota: State medical board guidance expects a hands-on initial evaluation for weight loss treatment.
• South Carolina: Requires an initial in-person visit and periodic evaluations for obesity treatment.
• Texas: While telehealth is broadly permitted, the standard of care generally dictates an initial in-person exam for weight loss prescriptions.
• Utah: State guidelines recommend an in-person baseline evaluation.
• Virginia: Board of Medicine rules mandate an initial physical exam, lab tests, and a personalized diet/exercise plan, with follow-up within 30 days of starting therapy.

States with No In-Person Requirement

Many states have embraced telehealth without mandating in-person visits for GLP-1 medications:

• California: Telehealth exams are sufficient; no in-person requirement.
• Connecticut: No in-person mandate, but providers must include behavioral counseling and diet/exercise planning for obesity treatment.
• Florida: No in-person exam required, though the state imposes conditions like BMI ≥30 and follow-up visits at least every 3 months.
• Illinois: No special in-person requirements beyond standard telehealth protocols.
• New York: Telehealth exam is sufficient; no in-person visit needed.
• Pennsylvania: No in-person mandate for GLP-1 prescriptions via telehealth.
• Washington: No in-person requirement; one of the most telehealth-friendly states.

Special State Requirements to Watch For

Florida requires that patients:

• Have a BMI of 30 or higher (or 27+ with comorbidities)
• Attend follow-up appointments at least once every three months during treatment

Connecticut mandates that obesity treatment include:

• Behavioral counseling
• A comprehensive diet and exercise plan alongside medication

Virginia requires:

• Initial physical exam and laboratory work
• A personalized diet/exercise plan
• Follow-up within 30 days of starting medication

These requirements don’t prohibit telehealth—they simply ensure that virtual care meets the same standards as in-person treatment.

Who Can Prescribe Weight Loss Medications Via Telehealth?

Physicians (MDs and DOs)

All states allow licensed physicians (Medical Doctors and Doctors of Osteopathy) to prescribe GLP-1 medications via telehealth, provided they hold an active license in the state where the patient is located.

Nurse Practitioners (NPs) and Physician Assistants (PAs)

The prescribing authority for NPs and PAs varies significantly by state:

Full Independent Practice (NPs can prescribe without physician oversight):

• California
• Connecticut (after 3 years of collaboration)
• Delaware (after 2 years)
• New York (after 3,600 hours of experience)
• North Dakota
• Utah
• Washington

Collaborative Practice (NPs/PAs can prescribe with physician agreement):

• Arkansas
• Florida (limited autonomy for NPs in primary care only)
• Georgia (recent law now allows NP/PA to prescribe Schedule II with physician delegation)
• Illinois
• Mississippi
• New Jersey
• Pennsylvania
• South Carolina
• Texas (strict oversight; NPs must have formal physician agreement)

Important note: Even in states requiring collaboration, NPs and PAs can legally prescribe GLP-1 medications for weight loss. The key is ensuring they’re working within their state’s scope of practice guidelines.

At Klarity Health, we work exclusively with licensed, credentialed providers who operate in full compliance with their state’s regulations—whether that’s an independent NP in Washington or a collaborative NP in Texas. You can feel confident that your prescriber is qualified and authorized to provide your care.

What to Expect During a Telehealth Weight Loss Consultation

Initial Evaluation

A legitimate telehealth provider will conduct a thorough evaluation before prescribing any weight loss medication. Expect to:

1. Complete a detailed medical questionnaire covering:

• Current height and weight (to calculate BMI)
• Medical history, including thyroid conditions, pancreatitis, or gallbladder disease
• Current medications and allergies
• Previous weight loss attempts
• Family history of thyroid cancer or Multiple Endocrine Neoplasia Type 2 (MEN2)

1. Participate in a live video consultation with a licensed provider who will:

• Review your medical history
• Discuss your weight loss goals
• Explain how GLP-1 medications work
• Review potential side effects and contraindications
• Create a treatment plan that includes lifestyle modifications

1. Receive informed consent documentation that outlines:

• Expected benefits and risks of treatment
• Common side effects (nausea, GI upset, potential gallstone formation)
• The importance of diet and exercise alongside medication
• Follow-up requirements

Clinical Criteria for Prescribing

Reputable telehealth providers follow evidence-based criteria when prescribing weight loss medications:

Generally required:

• BMI ≥30 (obesity)
• OR BMI ≥27 with weight-related comorbidities (diabetes, hypertension, high cholesterol, sleep apnea)
• Age 18 or older
• Willingness to commit to lifestyle changes

Common contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia Type 2 (MEN2)
• Pregnancy or planning to become pregnant
• Active gallbladder disease
• History of pancreatitis
• Severe gastrointestinal disorders

Follow-Up and Monitoring

Quality telehealth care doesn’t end with the initial prescription. Expect:

• Initial follow-up within 1 month to assess tolerance and adjust dosage
• Ongoing check-ins every 2-3 months to monitor progress and side effects
• Periodic lab work (metabolic panel, A1C) as clinically indicated
• Documentation of weight changes and lifestyle modifications

Some states mandate specific follow-up timelines:

• Florida: At least one follow-up every 3 months
• Virginia: Check-in within 30 days of starting medication

At Klarity Health, our providers maintain consistent follow-up schedules to ensure your treatment is safe, effective, and aligned with your goals. We accept both insurance and cash pay options, making ongoing care accessible and affordable.

Understanding Your Prescription Options

Wegovy (Semaglutide 2.4mg)

• FDA Status: Approved specifically for chronic weight management
• Schedule: Unscheduled (not a controlled substance)
• Telehealth: Fully prescribable via telemedicine
• Typical Supply: 30 days initially, up to 90 days for stable patients
• Special Notes: FDA-approved for patients with BMI ≥30 or ≥27 with comorbidities. Should be prescribed alongside lifestyle counseling.

Ozempic (Semaglutide 0.5–1mg)

• FDA Status: Approved for Type 2 diabetes; used off-label for weight loss
• Schedule: Unscheduled
• Telehealth: Prescribable via telemedicine with proper documentation
• Typical Supply: 30-day trial
• Special Notes: When prescribed off-label for weight loss, providers must document the rationale and obtain informed consent. Not intended for patients without diabetes unless obesity criteria are met.

Mounjaro (Tirzepatide) / Zepbound

• FDA Status: Mounjaro approved for diabetes; Zepbound approved for obesity
• Schedule: Unscheduled
• Telehealth: Fully prescribable via telemedicine
• Typical Supply: 30 days (titration packs)
• Special Notes: Dual GIP/GLP-1 agonist. Patients require training on self-injection technique.

Important: The Compounding Ban

In May 2025, the FDA declared the shortage of brand-name semaglutide over and banned most compounded versions of these medications due to safety concerns. This means:

• Legitimate telehealth providers can only prescribe FDA-approved brand medications
• ‘Compounded semaglutide’ from online sources may be illegal or unsafe
• Beware of services offering significantly cheaper ‘generic’ versions—these may not be legitimate

Red Flags: How to Identify Unsafe Telehealth Providers

As demand for weight loss medications has surged, so have questionable online services. Protect yourself by watching for these warning signs:

🚩 Guaranteed Prescriptions Without Evaluation

If a service promises you’ll definitely get a prescription before conducting a thorough medical assessment, that’s a major red flag. Legitimate providers evaluate each patient individually and will decline to prescribe if it’s not medically appropriate.

🚩 Selling Compounded or ‘Generic’ Versions

Since the FDA ban on compounded semaglutide, any service offering cheaper compounded alternatives is operating outside regulatory guidelines and potentially putting your health at risk.

🚩 No Real Provider Interaction

Some websites use automated questionnaires with minimal or no actual provider consultation. Safe telehealth requires live interaction with a licensed clinician who can assess your unique situation.

🚩 Lack of Follow-Up

Weight loss medication requires ongoing monitoring. If a service doesn’t schedule regular check-ins or make it easy to contact your provider with concerns, look elsewhere.

🚩 Unclear Provider Credentials

You should always know:

• Who your provider is (name and credentials)
• What state they’re licensed in
• How to contact them with questions

If this information isn’t transparent, it’s a warning sign.

🚩 Pressure Tactics or Unrealistic Claims

Be wary of services that:

• Promise rapid weight loss without effort
• Downplay side effects
• Pressure you to start treatment immediately
• Make guarantees about results

What Legitimate Telehealth Looks Like

Quality providers like Klarity Health:

• Conduct comprehensive medical evaluations
• Provide live video consultations with licensed clinicians
• Clearly explain risks, benefits, and alternatives
• Schedule regular follow-ups
• Prescribe only FDA-approved medications
• Accept both insurance and cash pay options
• Offer transparent pricing
• Make providers readily available for questions

The Future of Telehealth for Weight Loss

Current Regulatory Status

The telehealth landscape for weight loss medications is stable and expanding. Key developments to watch:

Federal Level:

• DEA’s telehealth flexibilities for controlled substances continue through December 31, 2025, with expectations for further extension or permanent rules in 2026
• Bipartisan Congressional support for telehealth access, including the TREATS Act introduced in October 2025
• Medicare coverage expansions for obesity counseling (though not yet for the medications themselves)

State Level:

• Trend toward more permissive telehealth regulations
• Growing number of states granting NPs full practice authority (34 states plus DC as of 2025)
• Interstate medical licensure compacts making it easier for providers to serve patients across state lines

What This Means for Patients

Telehealth access to weight loss medications is here to stay. As regulations continue to modernize, you can expect:

• Greater convenience: More states removing barriers to telehealth prescribing
• Improved access: Expanded provider networks as NP authority grows
• Better continuity: Easier transitions if you move between states
• Enhanced safety: Continued regulatory oversight ensuring quality standards

How Klarity Health Makes Weight Loss Treatment Simple

At Klarity Health, we’ve designed our telehealth platform to make accessing weight loss medications as straightforward and safe as possible:

Provider Availability

Our network of licensed providers is available across multiple states, with appointments typically available within days—not weeks or months.

Transparent Pricing

We believe healthcare costs should be clear upfront. Whether you’re using insurance or paying cash, you’ll know exactly what to expect before your consultation.

Both Insurance and Cash Pay Options

We accept major insurance plans and offer affordable cash-pay rates for those without coverage or preferring self-pay.

Comprehensive Care

Your treatment includes:

• Initial video consultation with a licensed provider
• Ongoing medication management
• Regular check-ins to monitor progress
• Access to provider messaging for questions
• Coordination with your preferred pharmacy

State-Specific Compliance

Our providers are fully licensed in your state and follow all local regulations—whether that’s scheduling an in-person exam when required or ensuring proper follow-up intervals.

Frequently Asked Questions

Q: Do I need an in-person visit before getting Wegovy or Ozempic through telehealth?

A: It depends on your state. Under federal law, no in-person visit is required for non-controlled medications like GLP-1s. However, some states (including Arkansas, Georgia, New Jersey, and Virginia) do require an initial in-person examination. Check the state-specific table earlier in this article for your location’s requirements.

Q: Can nurse practitioners prescribe weight loss medications via telehealth?

A: Yes, in all states. The level of physician oversight required varies by state—some states allow NPs to practice independently, while others require a collaborative agreement with a physician. Regardless, NPs can legally prescribe GLP-1 medications when working within their state’s scope of practice.

Q: Is it safe to get weight loss medications through telehealth?

A: Yes, when using a legitimate, regulated telehealth provider. Safe telehealth includes comprehensive medical evaluation, live provider interaction, informed consent, and regular follow-up monitoring—just like in-person care. The key is choosing a reputable provider that follows medical standards and regulatory requirements.

Q: How much do these medications cost through telehealth?

A: Costs vary based on insurance coverage. With insurance, copays typically range from $25 to $150 per month. Without insurance, cash prices for brand-name medications range from $900 to $1,400 per month. At Klarity Health, we help you understand your coverage and find the most affordable option.

Q: What if I move to a different state during treatment?

A: Your provider must be licensed in the state where you’re physically located during consultations. If you move, you may need to transfer care to a provider licensed in your new state. Klarity Health’s multi-state network makes this transition easier.

Q: Can I get these medications if I’m only slightly overweight?

A: Clinical guidelines and responsible prescribing require a BMI of at least 30 (or 27 with weight-related health conditions). These are powerful medications intended for medical obesity treatment, not cosmetic weight loss. Legitimate providers will only prescribe when medically appropriate.

Take the Next Step in Your Weight Loss Journey

If you’re ready to explore whether GLP-1 medications are right for you, telehealth offers a convenient, legitimate path forward. The key is choosing a provider that prioritizes your safety while making care accessible.

Klarity Health offers:

• Quick appointment availability with licensed providers
• Transparent, affordable pricing for both insured and cash-pay patients
• Comprehensive care that includes evaluation, prescription management, and ongoing support
• Full regulatory compliance with your state’s telehealth requirements

Ready to get started?

Schedule your consultation with Klarity Health today. Our providers will conduct a thorough evaluation, answer all your questions, and create a personalized treatment plan that fits your life—all from the comfort of your home.

Book Your Consultation or call our care team to learn more about how telehealth weight loss treatment can work for you.

This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider about your individual health needs and treatment options.

References

1. DEA and HHS Extend Telemedicine Flexibilities through 2025. Drug Enforcement Administration. November 15, 2024. Available at: https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. COVID-era telehealth prescribing extended for controlled substances. Axios. November 18, 2024. Available at: https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

3. McDermott Will & Emery. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025. November 18, 2024. Available at: https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/

4. Goodwin Procter LLP. The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs. March 27, 2024. Available at: https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. Nextech. Know Your State’s Laws Around Semaglutide. April 11, 2025. Available at: https://www.nextech.com/blog/semaglutide-laws-by-state

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid